• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Evaluation of the Safety of Slow IV Push Versus Slow IV Infusion Administration of 23.4% Sodium Chloride.23.4% 氯化钠静脉缓慢推注与静脉缓慢滴注给药安全性的评估。
Neurohospitalist. 2024 Apr;14(2):122-128. doi: 10.1177/19418744231216851. Epub 2023 Nov 27.
2
Efficiency and safety of high-dose undiluted intravenous push levetiracetam loading doses compared to intravenous infusion in seizing patients: A retrospective cohort study.高剂量未稀释静脉推注左乙拉西坦负荷剂量与静脉输注在癫痫发作患者中的疗效和安全性比较:一项回顾性队列研究。
Epilepsia. 2024 Oct;65(10):2888-2896. doi: 10.1111/epi.18079. Epub 2024 Aug 10.
3
Safety and Tolerability of 23.4% Hypertonic Saline Administered Over 2 to 5 Minutes for the Treatment of Cerebral Herniation and Intracranial Pressure Elevation.2%至5%高渗盐水静脉输注治疗脑疝和颅内压升高的安全性和耐受性。
Neurocrit Care. 2023 Apr;38(2):312-319. doi: 10.1007/s12028-022-01604-1. Epub 2022 Sep 28.
4
Safety of Intravenous Push Lacosamide Compared With Intravenous Piggyback at a Tertiary Academic Medical Center.静脉推注拉考沙胺与在三级学术医疗中心静脉推注相比的安全性。
Ann Pharmacother. 2021 Feb;55(2):181-186. doi: 10.1177/1060028020943569. Epub 2020 Jul 19.
5
Safety of Intravenous Push Valproate Compared with Intravenous Piggyback at a Tertiary Academic Medical Center.静脉推注丙戊酸钠与在三级学术医疗中心行静脉滴注推注相比的安全性。
Clin Drug Investig. 2024 Mar;44(3):175-181. doi: 10.1007/s40261-024-01349-z. Epub 2024 Feb 16.
6
Safety of Intravenous Push Levetiracetam Compared to Intravenous Piggyback at a Tertiary Academic Medical Center: A Retrospective Analysis.在一家三级学术医疗中心,静脉推注左乙拉西坦与静脉滴注相比的安全性:一项回顾性分析。
Drug Saf. 2022 Jan;45(1):19-26. doi: 10.1007/s40264-021-01122-7. Epub 2021 Oct 29.
7
Safety Profile of High-Dose Intravenous Push Lacosamide.高剂量静脉推注拉科酰胺的安全性概况
Neurohospitalist. 2023 Jul;13(3):278-282. doi: 10.1177/19418744231166984. Epub 2023 May 17.
8
Evaluation of Safety Outcomes of Undiluted Levetiracetam Intravenous Push Compared to Intravenous Piggyback.左乙拉西坦静脉推注与静脉滴注比较的安全性结局评估。
J Pharm Pract. 2024 Jun;37(3):722-727. doi: 10.1177/08971900231176457. Epub 2023 May 26.
9
Safety of Intravenous Push Ertapenem Compared to Intravenous Piggyback at a Tertiary Academic Medical Center.静脉推注厄他培南与在三级学术医疗中心行静脉滴注推注相比的安全性。
J Pharm Pract. 2023 Apr;36(2):281-285. doi: 10.1177/08971900211038355. Epub 2021 Aug 12.
10
Evaluation of First-Dose, Intravenous Push Penicillins and Carbapenems in the Emergency Department.急诊科首剂静脉推注青霉素类和碳青霉烯类药物的评价。
J Pharm Pract. 2022 Jun;35(3):369-376. doi: 10.1177/0897190020977758. Epub 2020 Dec 11.

本文引用的文献

1
Safety and Tolerability of 23.4% Hypertonic Saline Administered Over 2 to 5 Minutes for the Treatment of Cerebral Herniation and Intracranial Pressure Elevation.2%至5%高渗盐水静脉输注治疗脑疝和颅内压升高的安全性和耐受性。
Neurocrit Care. 2023 Apr;38(2):312-319. doi: 10.1007/s12028-022-01604-1. Epub 2022 Sep 28.
2
Safety and Efficacy of 23.4% Sodium Chloride Administered via Peripheral Venous Access for the Treatment of Cerebral Herniation and Intracranial Pressure Elevation.外周静脉输注 23.4% 氯化钠治疗脑疝和颅内压升高的安全性和有效性。
Neurocrit Care. 2021 Dec;35(3):845-852. doi: 10.1007/s12028-021-01248-7. Epub 2021 Jun 25.
3
23.4% Sodium Chloride Versus Mannitol for the Reduction of Intracranial Pressure in Patients With Traumatic Brain Injury: A Single-Center Retrospective Cohort Study.23.4% 氯化钠与甘露醇降低创伤性脑损伤患者颅内压的效果比较:一项单中心回顾性队列研究。
Ann Pharmacother. 2021 Aug;55(8):988-994. doi: 10.1177/1060028020982379. Epub 2020 Dec 21.
4
Vasopressor dose equivalence: A scoping review and suggested formula.血管加压药等效剂量:范围综述和建议公式。
J Crit Care. 2021 Feb;61:233-240. doi: 10.1016/j.jcrc.2020.11.002. Epub 2020 Nov 14.
5
Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients.神经危重症患者脑水肿急性治疗指南。
Neurocrit Care. 2020 Jun;32(3):647-666. doi: 10.1007/s12028-020-00959-7.
6
Efficacy, Safety, and Timing of 5% Sodium Chloride Compared With 23.4% Sodium Chloride for Osmotic Therapy.5%氯化钠与23.4%氯化钠用于渗透疗法的疗效、安全性及时机比较
Ann Pharmacother. 2017 Aug;51(8):625-629. doi: 10.1177/1060028017701220. Epub 2017 Mar 20.
7
Safety and efficacy of repeated doses of 14.6 or 23.4 % hypertonic saline for refractory intracranial hypertension.重复剂量的14.6%或23.4%高渗盐水治疗难治性颅内高压的安全性和有效性。
Neurocrit Care. 2014 Jun;20(3):436-42. doi: 10.1007/s12028-013-9907-1.
8
Repeated dosing of 23.4% hypertonic saline for refractory intracranial hypertension. A case report.重复给予23.4%高渗盐水治疗难治性颅内高压:一例报告
J Vasc Interv Neurol. 2008 Oct;1(4):113-7.
9
Treatment of elevated intracranial pressure with hyperosmolar therapy in patients with renal failure.肾衰竭患者颅内压升高的高渗治疗。
Neurocrit Care. 2012 Dec;17(3):388-94. doi: 10.1007/s12028-012-9676-2.
10
Hypertonic saline reduces intracranial hypertension in the presence of high serum and cerebrospinal fluid osmolalities.高张盐水可降低高血清和脑脊液渗透压时的颅内压。
Neurocrit Care. 2012 Oct;17(2):204-10. doi: 10.1007/s12028-011-9574-z.

23.4% 氯化钠静脉缓慢推注与静脉缓慢滴注给药安全性的评估。

Evaluation of the Safety of Slow IV Push Versus Slow IV Infusion Administration of 23.4% Sodium Chloride.

作者信息

Iskaros Olivia, Arnouk Serena, Papadopoulos John, Merchan Cristian

机构信息

New York University Langone Health, Brooklyn, NY, USA.

New York University Langone Health, New York, NY, USA.

出版信息

Neurohospitalist. 2024 Apr;14(2):122-128. doi: 10.1177/19418744231216851. Epub 2023 Nov 27.

DOI:10.1177/19418744231216851
PMID:38666283
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11040622/
Abstract

BACKGROUND AND PURPOSE

Increased intracranial pressure due to cerebral edema is a medical emergency in which 23.4% sodium chloride (23.4% NaCl) may be a lifesaving intervention. Currently, safety data is limited on slow IV push (IVP) administration. The purpose of this study was to evaluate the safety of IVP administration of 23.4% NaCl and determine the number of infusion-related adverse events (IRAEs) compared to slow IV infusion (SIV) administration.

METHODS

We performed a retrospective review of patients who received a dose of 23.4% NaCl at the from January 2015 to June 2020 as either SIV over 30 minutes or IVP over 2-5 minutes.

RESULTS

In total, 81 patients, 55 in the IVP group and 26 in the SIV group, were included in the analysis. There was a significantly faster time from order entry to dose completion (IVP 25 [13,58] vs SIV 73 [55,113] minutes, < .001). There was no difference in IRAEs between the groups (IVP 17 [31%] vs SIV 6 [23%], = .466). Hypotension was most common (IVP 13 [24%] vs SIV 5 [19%], = .656) followed by bradycardia (IVP 6 [11%] vs SIV 1 [4%], = .291). There were no extravasations reported.

CONCLUSIONS

Overall, among a cohort of patients with cerebral edema, we found no difference in the incidence of IRAEs between SIV and IVP administration of 23.4% NaCl, and found a faster time to complete administration fssor the latter. In emergent scenarios where time may impact neurologic function, 23.4% NaCl administered IVP may be an alternative to SIV administration.

摘要

背景与目的

脑水肿导致的颅内压升高是一种医疗急症,23.4% 氯化钠(23.4% NaCl)可能是一种挽救生命的干预措施。目前,关于缓慢静脉推注(IVP)给药的安全性数据有限。本研究的目的是评估23.4% NaCl静脉推注给药的安全性,并确定与缓慢静脉输注(SIV)给药相比,输液相关不良事件(IRAEs)的数量。

方法

我们对2015年1月至2020年6月期间接受一剂23.4% NaCl的患者进行了回顾性研究,给药方式为30分钟内缓慢静脉输注或2 - 5分钟内静脉推注。

结果

总共81例患者纳入分析,其中静脉推注组55例,缓慢静脉输注组26例。从医嘱录入到给药完成的时间,静脉推注组显著更快(静脉推注组25 [13,58]分钟 vs 缓慢静脉输注组73 [55,113]分钟,P <.001)。两组间输液相关不良事件无差异(静脉推注组17例 [31%] vs 缓慢静脉输注组6例 [23%],P =.466)。低血压最为常见(静脉推注组13例 [24%] vs 缓慢静脉输注组5例 [19%],P =.656),其次是心动过缓(静脉推注组6例 [11%] vs缓慢静脉输注组1例 [4%],P =.291)。未报告有外渗情况。

结论

总体而言,在一组脑水肿患者中,我们发现缓慢静脉输注和静脉推注23.4% NaCl的输液相关不良事件发生率无差异,且静脉推注完成给药的时间更快。在时间可能影响神经功能的紧急情况下,静脉推注23.4% NaCl可能是缓慢静脉输注的一种替代方法。